Synlogic rises on 'rare pediatric disease' tag for blood disorder treatment

Synlogic

19/01/2023 12:32

** Shares of drug developer Synlogic Inc  SYBX.O  gain ~13%
to $1.12 premarket 
    ** Co says it has received rare pediatric disease
designation from the U.S. FDA for its experimental therapy, 
SYNB1934 
    ** The therapy is being studied as a potential treatment for
phenylketonuria, which is an inherited disorder that increases
the levels of a substance called phenylalanine in the blood
    ** Synlogic plans to start a late-stage study for SYNB1934
drug in H1 of 2023
    ** Cos that receive approval for a rare pediatric disease
drug may be eligible to receive a transferable voucher for a
priority review of an application for another drug
    ** SYBX shares down 9% in the past three months 
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))